BRCA - Breast invasive carcinoma

Subtype	Proliferation	Prognosis	Therapy	Common Driver Mutations
Luminal A	Low	Best 5-year survival (~90%)	Endocrine therapy alone (e.g. tamoxifen, aromatase inhibitors)	**PIK3CA** (~45%), **GATA3, MAP3K1, TBX3**
Luminal B	Moderate–High	Intermediate (~80–85%)	Endocrine + chemotherapy (often add CDK4/6 inhibitors)	**TP53** (~30%), **PIK3CA** (~30%), **CCND1** amplification
HER2-Enriched	High	Historically poor (~75%)	Anti-HER2 agents (trastuzumab, pertuzumab, T-DM1) ± chemotherapy	**ERBB2** amplification, **TP53**, **PIK3CA**
Basal-Like	Very High	Poorest (~60–70%)	Chemotherapy (platinum-based); PARP inhibitors if BRCA-deficient	**TP53** (>80%), **BRCA1/2**, **RB1** loss
Normal-Like	Low (stroma signal)	Similar to Luminal A (debated)	Typically treated like Luminal A (endocrine)	Similar spectrum to Luminal A, but signal may reflect normal tissue contamination